Masthead

nCounter®
PanCancer Pathways Panel

Masthead

Helping Your Research

Gene expression profiling can be challenging because reproducibility and data analysis can be extremely demanding. The nCounter PanCancer Pathways Panel offers fast and high-throughput multiplex gene expression analysis solution for human or mouse genes. Each panel comes with 770 genes from 13 cancer-associated canonical pathways to support the understanding of basic cancer biology:

  • Measure treatment effects on pathways 
  • Score pathway deregulation with end-to-end analysis 
  • Generate follow-up research hypothesis using pathway visualizations 
  • Rapidly and easily screen samples for biomarker discovery or drug mechanism of action studies

Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.

How It Works

The nCounter PanCancer Pathways Panel come with simple workflow of less than 15 minutes hands-on time and streamlined analysis for data in under 24 hours.

*All nCounter Panel products are provided as a CodeSet product sold in increments of 12 reactions. Master Kits (for MAX or FLEX systems) or SPRINT Reagents and Cartridges (for SPRINT) are also required and sold separately.

01:

Highly multiplexed analysis of basic cancer biology and pathway deregulation activity 

02:

Measure gene expression with 770 genes representing all major cancer pathways including: Wnt, Hedgehog, apoptosis, cell cycle, RAS, PI3K, STAT, MAPK, Notch, TGF-β, chromatin modification, transcriptional regulation, and DNA damage control

03:

Customizable with up to 55 additional user-defined genes with Panel Plus option 

04:

3D-enabled for multi-analyte analysis with Vantage 3D™ Assays 

In The Lab

Hallmarks of Cancer Supplement

Read More
Hallmarks of Cancer

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Specifications
Signature/Pathways
Catalog Information
Product Comparison
Specifications
Signature/Pathways

Pathway Gene Coverage

Below are brief descriptions of the Pathways included in the PanCancer Pathways Panel. Please click on the name of the pathway to view more information, including detailed information on pathway genes and KEGG pathway gene maps

Catalog Information
Product Comparison

360 Series Product Comparison

Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.

Related Resources

See All Resources
Product Bulletin Hallmarks of Cancer – Product Bulletin
Whitepaper PanCancer-Pathways – Whitepaper
Whitepaper PanCancer Pathways nSolver Analysis Module – Whitepaper

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.

The addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved pathological complete response (pCR) rates in early-stage, HER2-positive breast cancer. Nonetheless, up to 50% of patients have residual disease after treatment, while others are likely overtreated.

Molecular risk markers related to local tumor recurrence at histological margin-free endoscopically resected early gastric cancers: A pilot study.

Local recurrences in early gastric cancers (EGCs) after complete endoscopic submucosal dissection (ESD) remain problematic. Here, we investigated the spatially sequential molecular changes in various cancer-related proteins along the axis of the histologically clear but recurrent resection margins (TRM) to determine the appropriate tumor-free margin distance and potential molecular risk markers related to local recurrence.

PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications.

Background: PAM50 breast cancer intrinsic subtyping adds prognostic information in early breast cancer; however, the role in metastatic disease is unclear. We aimed to identify PAM50 subtypes in primary tumors (PTs) and metastases to outline subtype changes and their prognostic role.

Skysphere

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us